Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of Pharmacology, Faculty of Medicine, Uni...

Full description

Bibliographic Details
Main Authors: Schiestl M, Zabransky M, Sörgel F
Format: Article
Language:English
Published: Dove Medical Press 2017-05-01
Series:Drug Design, Development and Therapy
Subjects:
biosimilars
regulatory pathways
Omnitrope®
Online Access:https://www.dovepress.com/ten-years-of-biosimilars-in-europe-development-and-evolution-of-the-re-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/ten-years-of-biosimilars-in-europe-development-and-evolution-of-the-re-peer-reviewed-article-DDDT

Similar Items